Shu Wang - 31 Mar 2023 Form 3 Insider Report for CytoMed Therapeutics Ltd (GDTC)

Reporting relationship
10%+ Owner
Issuer ticker
GDTC
Reported as of
31 Mar 2023
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
14 Apr 2023, 16:52:25 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Shu Wang

Key filing fact

Shu Wang filed Form 3 for CytoMed Therapeutics Ltd (GDTC) on 14 Apr 2023.

Key facts

  • This page summarizes Shu Wang's Form 3 filing for CytoMed Therapeutics Ltd (GDTC).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 14 Apr 2023, 16:52.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GDTC holding

Ordinary Shares, no par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
883,858
Date
31 Mar 2023
Ownership
Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .